1. Provision of written informed consent

2. Patients who take PSA test regularly

3. Observation suitable patients for PSA change according to hormonal treatment at least for 6months

4. Locally advanced or advanced prostate cancer patients who is suitable for hormonal therapy

5. Prostate Cancer Patients who has been taking one treatment among 3 hormonal therapies in below:

* Bicalutamide Monotherapy : Bicalutamide 150mg/day

* Goserelin 3.6mg/10.8mg

* MAB(Maximal Androgen Blockade) :Bicalutamide 50mg + Goserelin 3.6/10.8mg

Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNts